Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Sunitinib Malate In Combination With Capecitabine In Patients With Advanced Or Metastatic Breast Cancer

NCT00662025 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00662025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00662025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Sunitinib Malate In Combination With Capecitabine In Patients With Advanced Or Metastatic Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
May 31, 2012
Enrollment
63 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic breast cancer